From The
Stage

Expert perspectives focused on the latest bioanalytical topic & trends
BioAgilytix Gene editing - genes therapy concept with nurse & DNA lab technician medical laboratory

Vector Innovation to Improve Gene Therapy Safety: A Credit to Scientific Tenacity

A new clinical trial by St. Jude Children’s Research Hospital for the treatment of SCID-X1 highlights a major advancement in gene therapy safety over recent years, in this case spurred by scientists who were courageous enough to push forward the development of safer vectors to overcome serious adverse events (SAEs) that were resulting from the previous generation of gene therapies developed for SCID-X1.

Read More »
DNA strand and Cancer Cell

Immunogenicity Assessment of Gene Therapy Compounds

By Dr. Arno Kromminga and Dr. Lydia Michaut

Gene therapy has experienced an exciting resurgence in the post-genomic era, but unwanted immunogenicity is still a concern. Our latest blog gives insight into the current concepts for designing an immunogenicity assessment strategy fitting the specific needs of a given gene therapy compound.

Read More »

Novel Gene Therapy Technique Creates a Breakthrough in Sickle Cell Anemia Treatment

Innovations in gene therapy solutions are being made every day, improving treatments and creating cures for many previously untreatable genetic diseases. In fact, According to a recent report on global trends in gene therapy, the number of gene therapy products in development doubled between 2012 and 2015. The exciting news is that, based on a recent study within the scientific community, sickle cell disease may soon be treatable with gene

Read More »

Speak To A Scientist





    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.